SOMERVILLE, Mass.–(BUSINESS WIRE)–#RNA—Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Frank D’Amelio, MBA, former Chief Operating Officer (COO) of Lucent and most recently former Chief Financial Officer (CFO) and Executive Vice President, Global Supply at Pfizer, is joining Sail’s Board of Directors.
Mr. D’Amelio brings to Sail’s board an accomplished record as a technology and pharmaceutical operations, finance and global supply executive. At Lucent, he played a critical role in its spinout from AT&T. At Pfizer, he led the acquisition and integration of Wyeth Pharmaceuticals, King Pharmaceuticals, Inc., Hospira Inc., Anacor Pharmaceuticals, Inc., and Medivation, Inc., for Pfizer, as well as the spin-off of their animal health business, Zoetis, and the sale of its nutrition business to Nestlé and its Capsugel business to KKR.
“I’m honored to be joining the Sail Biomedicines Board of Directors at a pivotal time for the company,” said Mr. D’Amelio. “Sail’s vision and platform, which builds on over eight years of experimentation, represents an exciting opportunity to generate new medicines and forge innovative relationships with partners. I look forward to contributing to the future growth and success of this incredibly exciting and unique organization, and working with John and the rest of Sail’s leadership.”
“We are delighted to welcome Frank to Sail’s Board of Directors. In addition to his demonstrated focus on value creation in both the tech and pharma industries over the course of his distinguished career, he has played a pivotal role in advancing the industry’s understanding of how to scale mRNA medicines, which we will benefit greatly from as we continue to advance Sail towards the clinic and beyond,” said John Mendlein, Ph.D., Executive Chairman, Sail Biomedicines and Executive Partner, Flagship Pioneering.
About Sail Biomedicines
Sail Biomedicines, a Flagship Pioneering company, is generating tomorrow’s medicines today through the language of life. Sail’s platform combines first-in-category translatable circular RNA technology (Endless RNA™ or eRNA), and proprietary programmable nanoparticles, utilizing natural components, to comprehensively program medicines for the first time. By leveraging its rapid prototyping and testing bioplatform, Sail is building a wealth of data, enabling unparalleled use of state-of-the-art AI techniques for the integrative design of RNA medicines with unprecedented performance and broad applicability. For more, visit www.sail.bio and follow us on X (formerly Twitter) @SailBiomeds and on LinkedIn.
Contacts
Georgina Vincent, press@sail.bio